Actively Recruiting
Study of IASO207 Injection to Test Safety and Early Effectiveness in Adults with Relapsed or Hard-to-Treat B-cell Malignancies
Led by Peking University People's Hospital · Updated on 2026-06-18
18
Participants Needed
1
Research Sites
678 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating IASO207 Injection in patients with relapsed or refractory B-cell malignancies, focusing on evaluating its safety, effectiveness, and appropriate dosing in a first-in-human, early phase clinical trial. This single-center, open-label study uses a dose-escalation design to explore different dose levels of the drug in patients who have not responded to standard treatments and have confirmed CD19-positive disease. IASO207 Injection is a novel drug designed to generate CD19 CAR-T cells in the body by targeting T cells directly. Participants receive a single infusion of IASO207 at one of three dose levels 5.0 x 108 TU, 1.0 x 109 TU, or 2.0 x 109 TU. The study monitors the safety and tolerability of these doses, along with pharmacokinetics, pharmacodynamics, and immune responses, to guide future clinical trials. During the study, participants undergo various assessments including monitoring for adverse events, dose-limiting toxicities, and laboratory tests up to two years after infusion. Researchers also evaluate treatment response rates, duration and time to response, progression-free survival, and overall survival. Pharmacokinetic and pharmacodynamic markers are measured at scheduled intervals, while participants are closely followed to assess safety and treatment effects throughout the study period.
CONDITIONS
Brief Title
IASO207 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
Research Team
J
Jin Lu, PhD
X
Xuelin Dou,PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here